These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33610610)

  • 1. Harmonized 3Rs-based non-mutagenic impurity qualification study designs developed using the results of an IQ consortium survey.
    Mitra MS; Datta K; Hutchinson R; Nicolette JJ; Pettersen JC; Wegesser TC; Bercu JP
    Regul Toxicol Pharmacol; 2021 Jun; 122():104895. PubMed ID: 33610610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calculating qualified non-mutagenic impurity levels: Harmonization of approaches.
    Graham JC; Powley MW; Udovic E; Glowienke S; Nicolette J; Parris P; Kenyon M; White A; Maisey A; Harvey J; Martin EA; Dowdy E; Masuda-Herrera M; Trejo-Martin A; Bercu J
    Regul Toxicol Pharmacol; 2021 Nov; 126():105023. PubMed ID: 34363920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-mutagenic impurities - Recent industry experience of using dose durational limits in drug development.
    Lortie A; Martin EA; Arnot K
    Regul Toxicol Pharmacol; 2024 Feb; 147():105559. PubMed ID: 38145838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New limits proposed for the management of non-mutagenic impurities.
    Slikkerveer A; Doehr O; Claude N; Hutchinson R; Harvey J; Spanhaak S
    Regul Toxicol Pharmacol; 2024 Jun; 150():105647. PubMed ID: 38777301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deriving acceptable limits for non-mutagenic impurities in medicinal products - Durational adjustments.
    Kenyon MO; Martin M; Martin EA; Brandstetter S; Wegesser T; Greene N; Harvey J
    Regul Toxicol Pharmacol; 2024 Jun; 150():105644. PubMed ID: 38761968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Qualification of impurities based on metabolite data.
    Weidolf L; Andersson T; Bercu JP; Brink A; Glowienke S; Harvey J; Hayes MA; Jacques P; Lu C; Manevski N; Muster W; Nudelman R; Ogilvie R; Ottosson J; Teasdale A; Trela B
    Regul Toxicol Pharmacol; 2020 Feb; 110():104524. PubMed ID: 31734179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of non-mutagenic substances in the context of drug impurity assessment - Few are potent toxicants.
    Hasselgren C; Kenyon M; Anger LT; Cornwell P; Watt E; Bercu J
    Regul Toxicol Pharmacol; 2024 Jun; 150():105645. PubMed ID: 38761967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control Strategy for Small Molecule Impurities in Antibody-Drug Conjugates.
    Gong HH; Ihle N; Jones MT; Kelly K; Kott L; Raglione T; Whitlock S; Zhang Q; Zheng J
    AAPS PharmSciTech; 2018 Apr; 19(3):971-977. PubMed ID: 29302872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of organic impurities in small molecule medicinal products: Deriving safe limits for use in early development.
    Harvey J; Fleetwood A; Ogilvie R; Teasdale A; Wilcox P; Spanhaak S
    Regul Toxicol Pharmacol; 2017 Mar; 84():116-123. PubMed ID: 28038978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International Conference on Harmonisation; revised guidance on Q3B(R) Impurities in New Drug Products; Availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Nov; 68(220):64628-9. PubMed ID: 14619944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of In Silico Methods for Regulatory Toxicological Assessment of Pharmaceutical Impurities.
    Kovarich S; Cappelli CI
    Methods Mol Biol; 2022; 2425():537-560. PubMed ID: 35188646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory Acceptance of Alternative Methods in the Development and Approval of Pharmaceuticals.
    Beken S; Kasper P; van der Laan JW
    Adv Exp Med Biol; 2016; 856():33-64. PubMed ID: 27671719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International Conference on Harmonisation; revised guidance on Q3A impurities in new drug substances; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Feb; 68(28):6924-5. PubMed ID: 12583358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of emerging safety biomarkers in nonclinical and clinical safety assessment - The current and future state: An IQ DruSafe industry survey.
    Zabka TS; Burkhardt J; Reagan WJ; Gautier JC; Glaab WE; Guffroy M; Harding J; Brees D; McDuffie E; Ramaiah L; Schultze AE; Smith JD; Wolfreys A; Dalmas DA
    Regul Toxicol Pharmacol; 2021 Mar; 120():104857. PubMed ID: 33387566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of genotoxic impurities in pharmaceutical development.
    Bercu JP; Dobo KL; Gocke E; McGovern TJ
    Int J Toxicol; 2009; 28(6):468-78. PubMed ID: 19966139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impurities in Oligonucleotide Drug Substances and Drug Products.
    Capaldi D; Teasdale A; Henry S; Akhtar N; den Besten C; Gao-Sheridan S; Kretschmer M; Sharpe N; Andrews B; Burm B; Foy J
    Nucleic Acid Ther; 2017 Dec; 27(6):309-322. PubMed ID: 29125795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Species selection for nonclinical safety assessment of drug candidates: Examples of current industry practice.
    Namdari R; Jones K; Chuang SS; Van Cruchten S; Dincer Z; Downes N; Mikkelsen LF; Harding J; Jäckel S; Jacobsen B; Kinyamu-Akunda J; Lortie A; Mhedhbi S; Mohr S; Schmitt MW; Prior H
    Regul Toxicol Pharmacol; 2021 Nov; 126():105029. PubMed ID: 34455009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Current Status and Use of Microphysiological Systems by the Pharmaceutical Industry: The International Consortium for Innovation and Quality Microphysiological Systems Affiliate Survey and Commentary.
    Baker TK; Van Vleet TR; Mahalingaiah PK; Grandhi TSP; Evers R; Ekert J; Gosset JR; Chacko SA; Kopec AK
    Drug Metab Dispos; 2024 Feb; 52(3):198-209. PubMed ID: 38123948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guidelines and pharmacopoeial standards for pharmaceutical impurities: overview and critical assessment.
    Snodin DJ; McCrossen SD
    Regul Toxicol Pharmacol; 2012 Jul; 63(2):298-312. PubMed ID: 22507740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of the impurities in drug products containing montelukast and in silico/in vitro genotoxicological assessments of sulfoxide impurity.
    Emerce E; Cok I; Degim IT
    Toxicol Lett; 2015 Oct; 238(2):90-9. PubMed ID: 26205398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.